methyl trans-4-(morpholin-4-ylcarbonyl)-cyclohexanecarboxylate | 412293-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: methyl trans-4-(morpholin-4-ylcarbonyl)-cyclohexanecarboxylate
• 英文别名: methyl trans-4-(morpholin-4-ylcarbonyl)cyclohexane carboxylate
• CAS: 412293-70-0
• 化学式: C₁₃H₂₁NO₄
• 分子量: 255.314
• InChiKey: BYLLNVIAVAMHOA-XYPYZODXSA-N

物化性质

• 沸点：
  402.3±45.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.82
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  55.84
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  methyl trans-4-(morpholin-4-ylcarbonyl)-cyclohexanecarboxylate 在 一水合肼 作用下， 以 乙醇 为溶剂， 以95 %的产率得到trans-4-(morpholin-1-ylcarbonyl)cyclohexane carboxylic acid hydrazide
  参考文献：
  名称：

  Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01868
• 作为产物：
  描述：

  吗啉 、 Trans-1,4-Cyclohexanedicarboxylic Acid Monomethyl Ester 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以60 %的产率得到methyl trans-4-(morpholin-4-ylcarbonyl)-cyclohexanecarboxylate
  参考文献：
  名称：

  Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01868

文献信息

• [EN] TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS<br/>[FR] TRIAZOLOBENZAZÉPINES UTILISÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA VASOPRESSINE V1A
  申请人：RICHTER GEDEON NYRT

  公开号：WO2019116324A1

  公开（公告）日：2019-06-20

  The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.

  本发明涉及一般式(I)的5,6-二氢-4H-[1,2,4]三唑并[4,3-a][1]苯并蒽啉衍生物和/或其盐和/或其几何异构体和/或其立体异构体和/或其对映异构体和/或其消旋体和/或其非对映异构体和/或其生物活性代谢物和/或其前药和/或其溶剂化合物和/或其水合物和/或其多晶形式，这些化合物是中枢和/或外周作用的V1a受体调节剂，特别是V1a受体拮抗剂。本发明的另一个主题是制备这些化合物的过程以及制备过程的中间体。该发明还涉及含有这些化合物或与一个或多个其他活性物质一起的药物组合物，以及在治疗和/或预防与V1a受体功能相关的疾病或症状中的用途。
• Fused furan compound
  申请人：Kawaguchi Takayuki

  公开号：US20060094724A1

  公开（公告）日：2006-05-04

  The present invention provides a condensed furan compound of the formula (I): wherein Ring X is benzene, pyridine, or the like; Y is an optionally substituted amino, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted saturated heterocyclic group, an optionally substituted unsaturated heterocyclic group; A is a single bond, lower alkylene, lower alkenylidene, lower alkenylene or an oxygen atom; R 3 is hydrogen or the like; and, R 4 is hydrogen, or the like, or pharmaceutically acceptable salts thereof, which is useful as a medicament, particularly, as an activated blood coagulation factor X inhibitor.

  本发明提供了式(I)的紧凑呋喃化合物：其中环X是苯、吡啶或类似物；Y是可选取代的氨基、可选取代的环烷基、可选取代的芳基、可选取代的饱和杂环基、可选取代的不饱和杂环基；A是单键、低级烷基、低级烯基亚烷基、低级烯基亚烯基或氧原子；R3是氢或类似物；R4是氢或类似物，或其药学上可接受的盐，其用作药物，特别是作为激活的血凝血酶X抑制剂。
• Aliphatic nitrogenous five-membered ring compounds
  申请人：——

  公开号：US20040063935A1

  公开（公告）日：2004-04-01

  The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: 1 wherein A represents —CH 2 — or —S—, R 1 represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group, X represents —N(R 3 )—, —O— or —CO—, where R 3 represents hydrogen atom or a lower alkyl group, and R 2 represents (1) a cyclic group which may be substituted, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof, a method for preparing the above-mentioned compound and a pharmaceutical composition comprising the above-mentioned compound as an effective ingredient.

  本发明提供了一种脂肪族氮含有5元环化合物，其化学式表示为[I]：其中，A代表—CH2—或—S—，R1代表氢原子、低碳基、羟基低碳基或低烷氧基低碳基，X代表—N(R3)—、—O—或—CO—，其中R3代表氢原子或低碳基，而R2代表(1)可能被取代的环状基团，或(2)可能被取代的氨基基团，或其药学上可接受的盐，以及制备上述化合物的方法和包含上述化合物作为有效成分的制药组合物。
• Aliphatic nitrogen - containing 5 - membered ring compound
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：US20040229926A1

  公开（公告）日：2004-11-18

  The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: 1 wherein A represents —CH 2 — or —S—, R 1 represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower-alkoxy lower alkyl group, X represents —N(R 3 )—, —O— or —CO—, where R 3 represents hydrogen atom or a lower alkyl group, and R 2 represents (1) a cyclic group which may be substituted, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof, a method for preparing the above-mentioned compound and a pharmaceutical composition comprising the above-mentioned compound as an effective ingredient.

  本发明提供一种脂肪族含氮的五元环化合物，其化学式为[I]:1，其中A代表—CH2—或—S—，R1代表氢原子、低碳基、羟基低碳基或低烷氧基低碳基，X代表—N(R3)—、—O—或—CO—，其中R3代表氢原子或低碳基，而R2代表(1)可能被取代的环状基团，或(2)可能被取代的氨基基团，或其药学上可接受的盐，以及制备上述化合物的方法和包含上述化合物作为有效成分的制药组合物。
• Carbamoyl-type benzofuran derivatives
  申请人：Kawaguchi Takayuki

  公开号：US20060247273A1

  公开（公告）日：2006-11-02

  The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R 4 and R 5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R 1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R 3 is a hydrogen atom. etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.

  本发明提供了一种公式[1]的氨基甲酰基苯并呋喃衍生物： 其中，环Z是公式等的一组；A是单键等；Y是环烷基二基等；R4和R5相同或不同，每个是可选取的低取代基等；R1是卤素原子等；环B是可选取的苯环；R3是氢原子等；或其药学上可接受的盐，作为FXa抑制剂具有用处。